Know Labs has developed a proprietary non-invasive diagnostic technology platform that utilizes radiofrequency (RF) dielectric spectroscopy to measure and identify a variety of organic and inorganic materials, including glucose levels. This innovative approach allows for continuous glucose monitoring without the need for invasive procedures such as finger pricks or the use of test strips. The technology is designed to be form factor agnostic, meaning it can be integrated into various devices, including wearables and mobile applications. The KnowU device, a key product from Know Labs, is a wearable continuous blood glucose monitor that connects to a mobile app, providing real-time glucose level readings and trends over time.

The RF dielectric spectroscopy technology employed by Know Labs involves rapidly scanning a wide range of RF frequencies to collect high-resolution data on glucose levels. This method not only enhances the accuracy of glucose measurements but also eliminates the need for costly consumables, making it a more affordable option compared to traditional blood glucose monitoring systems. With over 270 patents related to its technology, Know Labs is positioned as a leader in the field, aiming to improve diabetes management for millions of individuals worldwide while also exploring additional applications for its technology across various industries.

United States

Know Labs is transforming non-invasive medical diagnostics. The proprietary technology platform uses radiofrequency (RF) dielectric spectroscopy and can be integrated into a variety of wearable, mobile, or bench-top form factors. The first application is a non-invasive continuous blood glucose monitoring device that will provide the user with real-time information on their blood glucose levels, assisting billions of people with diabetes and prediabetes to manage this medical condition. Know Labs is a public company whose shares trade under the stock symbol KNW (NYSE American).

Know Labs

Company Details